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A B S T R A C T
Human OATP2B1 encoded by the SLCO2B1 gene is a multispecific transporter mediating the cellular uptake of
large, organic molecules, including hormones, prostaglandins and bile acids. OATP2B1 is ubiquitously expressed
in the human body, with highest expression levels in pharmacologically relevant barriers, like enterocytes,
hepatocytes and endothelial cells of the blood-brain-barrier. In addition to its endogenous substrates, OATP2B1
also recognizes clinically applied drugs, such as statins, antivirals, antihistamines and chemotherapeutic agents
and influences their pharmacokinetics. On the other hand, OATP2B1 is also overexpressed in various tumors.
Considering that elevated hormone uptake by OATP2B1 results in increased cell proliferation of hormone de-
pendent tumors (e.g. breast or prostate), inhibition of OATP2B1 can be a good strategy to inhibit the growth of
these tumors.
13-epiestrones represent a potential novel strategy in the treatment of hormone dependent cancers by the
suppression of local estrogen production due to the inhibition of the key enzyme of estrone metabolism, 17ß-
hydroxysteroid-dehydrogenase type 1 (HSD17ß1). Recently, we have demonstrated that various phosphonated
13-epiestrones are dual inhibitors also suppressing OATP2B1 function. In order to gain better insights into the
molecular determinants of OATP2B1 13-epiestrone interaction we investigated the effect of C-2 and C-4 halogen
or phenylalkynyl modified epiestrones on OATP2B1 transport function. Potent inhibitors (with EC50 values in
the low micromolar range) as well as non-inhibitors of OATP2B1 function were identified. Based on the
structure-activity relationship (SAR) of the various 13-epiestrone derivatives we could define structural elements
important for OATP2B1 inhibition. Our results may help to understand the drug/inhibitor interaction profile of
OATP2B1, and also may be a useful strategy to block steroid hormone entry into tumors.
1. Introduction
Organic anion-transporting polypeptides (OATPs) encoded by the
SLCO (solute carrier for organic anions) genes are membrane proteins
that mediate the cellular uptake of large (> 300 Da) organic molecules
in a Na+- and ATP-independent manner [1]. 11 human OATPs are
known, that are highly variable in their tissue distribution and substrate
recognition. Some OATPs are ubiquitously expressed in the human
body (OATP4A1, OATP3A1), while the expression of others is restricted
to a given organ, like OATP1B1 and OATP1B3 expression which is re-
stricted to hepatocytes [2,3]. Also, based on the substrate interaction
profile, multispecific OATPs (1A2, 1B1, 1B3, and 2B1) recognizing a
plethora of organic compounds (including clinically applied drugs), and
OATPs with a more limited substrate recognition (e.g., the thyroid
transporter OATP1C1) can be distinguished. Although not all of the 11
OATPs are properly characterized with regard to their expression and
function, steroids (e.g. bile acids, estrone-3-sulfate (E1S) and dehy-
droepiandrosterone sulfate (DHEAS)) can be considered as general
OATP substrates [4]. Consequently, the OATPs 1A2, 1B1, 2B1 and 4A1
are supposed to be key participants in the cellular uptake of the steroid
hormone conjugates E1S and DHEAS [3,5]. Besides their role in the
maintenance of steroid hormone homeostasis, multispecific OATPs,
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1A2, 1B1, 1B3 and 2B1 are important determinants of pharmacoki-
netics [6]. In addition, OATPs are often up-regulated in tumors [7–9].
Hence, they are promising targets for anti-tumor therapy.
OATP2B1 is a ubiquitously expressed transporter, with highest
protein levels in pharmacologically relevant barrier tissues, like the
intestine, liver and blood-brain barrier [1]. Besides, it is also expressed
in the placenta, mammary gland and in skeletal muscle cells [1].
OATP2B1 is a multispecific transporter that recognizes molecules with
largely variable size and structure. The most relevant endogenous
substances transported by OATP2B1 are taurocholate, leukotriene C4,
E1S, DHEAS and prostaglandin E2 [10]. OATP2B1 also promotes cel-
lular uptake of clinically applied drugs, like statins, antibiotics, anti-
hypertensives, anti-inflammatory drugs and chemotherapeutics [10].
Considering its tissue distribution and substrate recognition pattern,
OATP2B1 may be a key player in intestinal drug absorption and also
drug transport across the blood–brain barrier [11,12]. On the other
hand, OATP2B1 overexpression has been detected in tumors of the
colon, bone, breast, prostate and also in gliomas [13–15]. Considering
its transport of anti-cancer agents, OATP2B1 is one of the main candi-
dates of tumor-targeted drug delivery. On the other hand, it has been
shown that increased steroid hormone (E1S, DHEAS) uptake by
OATP2B1 promotes growth of steroid-dependent tumors. Matsumoto
and colleagues demonstrated that overexpression of OATP2B1 results in
increased survival of breast cancer cells in vitro [14]. Moreover, in vivo
data revealed that DHEAS uptake by OATP2B1 has crucial role in
prostate cancer progression [16]. Also, the SLCO2B1 rs12422149 GG
(Arg312Gln) genotype resulting in increased OATP2B1 function corre-
lates with shorter time to progression in prostate cancer patients who
received androgen deprivation therapy [17,18]. Therefore, inhibition of
OATP2B1 function presents a possible strategy to suppress steroid
hormone uptake and hence the proliferation of hormone dependent
cancers.
13-epiestrones are stereoisomers of natural estrone, lacking hor-
monal activity [19,20]. Previous work has demonstrated that certain
13-epiestrones are potent inhibitors of the 17ß-hydroxysteroid-dehy-
drogenase type 1 (HSD17ß1) and steroid sulfatase (STS) enzymes cru-
cial in estrone metabolism [21]. These enzymes are responsible for local
estrogen formation and generation of the transcriptionally active es-
tradiol therefore promoting proliferation of hormone dependent can-
cers [22,23]. Hence their inhibition e.g. by 13-epiestrones can be a
potential anti-tumor strategy.
Recently we found that phosphonated 13-epiestrones inhibit the
function of OATP2B1 [24]. In the current work, in order to get a better
insight into the molecular determinants involved in this inhibition we
analyzed the interaction between OATP2B1 and a large set of 13-
epiestrones containing modifications on C-3 and C-2 or C-4. In addition,
we systematically investigated the influence of certain substituents on
inhibitory activity by correlation analysis.
2. Materials and methods
2.1. Materials
Materials if not stated otherwise were purchased for Sigma Aldrich
(Budapest, Hungary). 13-epiestrones investigated in this study were
synthesized as described elsewhere [21,25].
2.2. Generation and maintenance of the cell lines
A431 (human epidermoid carcinoma) cells overexpressing human
OATP2B1 or mock transfected controls used in the current study were
generated earlier as described in [26]. Briefly, OATP2B1 expressing
cells were generated by transposase mediated genomic insertion of the
OATP2B1 cDNA (BC041095.1, HsCD00378878). As a negative control
mock transfected (pSB-CMV) cells were used. After 2 weeks of pur-
omycin (1μg/ml) selection, cells were sorted based on Live/Dead Green
uptake. After recovery, cell were grown in DMEM (Gibco, Thermo Fi-
scher Scientific (Waltham, MA, US)) without puromycin supplemented
with 10 % fetal calf serum, 2mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin at 37 °C with 5% CO2 and 95 % humidity.
2.3. Western blot detection of OATP2B1 expression
OATP2B1 expression was confirmed by Western blot as described
earlier [26]. Briefly, whole cell lysates of A431 cells were separated on
7.5 % SDS-PAGE gels and transferred onto a PVDF membrane.
OATP2B1 was detected by using an anti-OATP2B1 antibody (a courtesy
of Dr. Bruno Stieger, Department of Clinical Pharmacology and Tox-
icology, University Hospital, 8091 Zurich, Switzerland) [27]. As a
secondary antibody HRP-conjugated anti-rabbit antibody (Jackson
ImmunoResearch, Suffolk, UK) was used in a dilution of 20,000× . An
anti-β-actin antibody (A1978, Sigma) and HRP-conjugated anti-mouse
antibody (Jackson ImmunoResearch, Suffolk, UK, 20,000 x dilution)
were used to detect β-actin. Luminescence was detected using the Lu-
minor Enhancer Solution kit by Thermo Fisher Scientific (Waltham,
MA, US).
2.4. Fluorescent dye uptake determined by flow cytometry
The transport function of OATP2B1 was determined by flow cyto-
metry. A431 cells (mock and OATP2B1 overexpressing) were collected
after 0.1 % trypsin treatment. The cells were washed in Uptake buffer
(125mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2mM KH2PO4, 12mM
MgSO4, 25mM MES, and 5.6 mM glucose, with the pH adjusted to 5.5
using 1M HEPES and 1 N NaOH). After washing 5×105 cells were
incubated for 15min at 37 °C with Zombie Violet (BioLegend®, San
Diego, CA, US) (0.4 μl ZV/5× 105 cell) in a final volume of 100 μl. The
reaction was stopped by the addition of 1ml ice-cold PBS (phosphate
buffered saline) and the cells were kept on ice until the flow cytometry
analysis. The fluorescence of 10,000 living cells was determined using
Attune NxT Flow Cytometer (Invitrogen, Carlsbad, CA). Dead cells were
excluded by propidium iodide (1 μg/ml) labeling.
2.5. 96 well plate-based transport assay
Effect of 13-epiestrones on OATP2B1 function was determined by
measuring Zombie Violet (BioLegend®, San Diego, CA, US) fluorescent
dye uptake on microplates [26]. Briefly, A431 cells were seeded on 96
well-plates (8×104 cells in 200 μl final volume/well) and cultured for
16−24 h at 37 °C, 5% CO2 prior to the transport measurements. Next
day after repeated washing with 200 μl PBS, cells were pre-incubated
with 50 μl Uptake buffer (125mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2,
1.2 mM KH2PO4, 12mMMgSO4, 25mMMES, and 5.6mM glucose, with
the pH adjusted to 5.5 using 1M HEPES and 1 N NaOH) containing the
appropriate concentrations of the 13-epiestrones (0–100 μM) for 5min
at 37 °C. Reaction was started by the addition of 770 x diluted Zombie
Violet dye in 50 μl/well Uptake buffer followed by a 30min incubation
at 37 °C. The reaction was stopped by the addition of 200 μl ice-cold
PBS. After repeated washing, 200 μl ice-cold PBS was added to each
well and fluorescence in the wells was determined in an Enspire
fluorescent plate reader (Perkin Elmer, Waltham, MA) at Ex/Em: 405/
423 nm. Experiments were repeated at least three times.
2.6. Measurement of 3H-E1S uptake
A431 control and A431-OATP2B1 cells (106 cells/sample) were
incubated in the absence or presence of 2-bromo-13-epiestrone (final
concentration 50 μM) for 5min at 37 °C in uptake buffer pH 5.5.
Transport reaction was started by the addition of 3H-E1S (250mCi/ml,
final concentration 9.65 nM (Perkin Elmer, Waltham, MA)). After in-
cubation for further 10min at 37 °C, the reaction was stopped by the
addition of 1ml ice-cold PBS and the cells were centrifuged at 300 g.
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The cell pellet was collected in 100 μl PBS and pipetted into 1ml Opti-
Fluor (Perkin Elmer, Waltham, MA). Radioactivity was measured in a
Wallac Liquid Scintillator Counter. Experiments were repeated three
times.
2.7. Data calculation
Transport data were obtained by subtracting the fluorescence in
mock transfected cells from that measured in OATP2B1 cells. Kinetic
parameters of dye uptake and half inhibitory concentrations (EC50)
obtained from at least three independent experiments were determined
by Hill fit using the GraphPad prism software (GraphPad, La Jolla, CA,
USA).
2.8. Structure-activity relationship (SAR) analysis
Compounds were drawn using the structure editor integrated into
the ChemSpider chemical structure database webservice (freely avail-
able at https://www.chemspider.com/About.aspx). Daylight SMILES
structural format was generated for every unique compound of the
dataset. KNIME Analytics Platform (version 3.4) [28] was used to create
an automated workflow for Structure-Activity Relationship (SAR)
analysis of 13-epiestrones. First, Daylight SMILES format for input
compounds was converted into the canonical form (‘RDKit Canon
SMILES’ node). Murcko scaffolds were generated and the maximum
common substructure (MCS) was derived from the retrieved Murcko
scaffolds (‘RDKit MCS’ node). MCS was used as a structural query for
substructure mining in order to perform R-group decomposition (‘RDKit
R Group Decomposition’ node).
Physicochemical descriptors (RDKit) for the substituents (R groups)
at position C-2 and C-4 were calculated. Descriptor values were nor-
malized (‘Normalizer’ node using Z-score normalization). The Pearson
correlation coefficient was calculated to identify positive or negative
correlations between pEC50 values and respective physicochemical de-
scriptors at a given R-group position (‘Linear Correlation’ node).
3. Results
3.1. Effect of C-2 or C-4 halogenated 13-epiestrones on the transport
activity of OATP2B1
Recently, we have reported that various phosphonated 13-epies-
trones are potent inhibitors of OATP2B1 function [24]. In order to gain
better insights into the molecular determinants of this inhibition, we
investigated the inhibitory effect of various 2- or 4-halogenated 3-hy-
droxy- (3-OH) or 3-methoxy (3-OMe) 13-epiestrones (Fig. 1).
Interaction was measured in A431 mock transfected (control) and
OATP2B1 overexpressing cell lines using the Zombie Violet (ZV) assay.
The A431 cell line overexpressing OATP2B1 was generated earlier [26].
Prior to the interaction tests OATP2B1 overexpression was confirmed
by Western blot (Fig. 2A). ZV is one of the newly identified fluorescent
dyes applicable for testing drug interactions and function of OATP2B1,
and a good alternative to the generally used radioactive functional as-
says [26]. Fig. 2B shows that OATP2B1 overexpression results in in-
creased uptake of the viability dye, ZV.
When testing the inhibitory effect of the epiestrone derivatives, ZV
uptake was measured in A431-OATP2B1 (and control) cells seeded in
96-well plates in the presence of increasing amounts of the tested
compounds. As shown in Fig. 3, the compounds showed various degrees
of transport inhibition. The first striking difference could be observed
between the C-3 OH and OMe compounds. 13-epiestrone (C-3 OH,
termed as compound 1) had practically no effect on ZV transport (EC50
around 50 μM), while its methylether counterpart (3-OMe derivative,
compound 2) resulted in a quite effective inhibition (EC50 2.98 μM)
(see Fig. 3 and Table 1).
Interestingly, introduction of a second modification, halogenation of
either at C-2 or C-4 resulted in opposite changes in the inhibitory po-
tential of 13-epiestrones. In the case of compound 1, halogenation at C-
2 (compounds 1a_2, 1b_2 and 1c_2) resulted in a striking increase in
inhibitory potential, with EC50 values between 0.5 and 2.1 μM.
However, the C-4 chlorinated derivative (compound 1c_4) showed
practically no effect on OATP2B1 transport function, while 4-iodo and
4-bromo 13-epiestrones (1a_4 and 1b_4) proved to be weak inhibitors.
This reveals a strong dependence of the regioisomerism of the haloge-
nated 3-OH compounds, the most potent inhibition detected with the 2-
halogenated derivatives. In the case of 3-OMe derivatives, halogenation
caused lower alteration in the inhibitory potential, although all of the
compounds showed increased EC50 values compared to the initial
compound. Iodinated derivatives (2a_2 and 2a_4) were more effective
than the brominated or chlorinated compounds (2b_2, 2b_4 or 2c_2,
2c_4). Regioisomer specific inhibitory effect in the case of the 3-OMe
variants could only be observed for the chlorinated compounds, with an
approximately 5-fold increase in the EC50 of the C-4 vs. C-2 chlorinated
epiestrones (2c_2 and 2c_4, Table 1).
3.2. Effect of C-2 or C-4 phenylalkynylated 13-epiestrones on the transport
activity of OATP2B1
Next, we investigated the effect of the introduction of a pheny-
lalkynyl group in position C-2 or C-4 on OATP2B1 function (Fig. 4).
In the case of 3-OH 13-epiestrones, introduction of a large ring re-
sulted in various effects. In general, although some phenylalkynylated
13-epiestrones showed detectable interaction with OATP2B1, these
compounds were less effective inhibitors than the C-2 halogenated
epiestrones (see Table 2 and Fig. 5). The only exception is 1gS_4 con-
taining a (4-methoxyphenyl)ethynyl substituent, that was almost as
effective inhibitor as the C-2 halogenated 13-epiestrones. Interestingly,
in the case of phenylalkynylated 3-OH 13-epiestrones no clear rule in
preference in interaction with C-2 over C-4 modified compounds could
be observed. Compounds 1eS_4 and 1gS_4 were more potent inhibitors
than their C-2 counterparts (1eS_2 and 1gS_2). However, in the case of
13-epiestrones bearing fluorinated substituents (1hS and 1fS), this
tendency changed, C-2 compounds being slight inhibitors (EC50 around
10 μM) compared to C-4 modified derivatives lacking any inhibitory
potential (at least in the concentrations tested).
In the case of the 3-OMe compounds with a second, subst. pheny-
lalkynyl modification, similarly to that observed for the halogenated
Fig. 1. Structure of the halogenated 13-epiestrones investigated in the current
study. In the case of compounds 1 and 2 X1=H and X2=H.
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compounds, a decrease or even a complete loss of inhibition compared
to the parental compound 3-OMe 13-epiestrone could be observed. The
only exceptions were compounds 2gS_2 and 2gS_4 that proved to be
effective inhibitors. A clear rule of regioselectivity could not be ob-
served for the 3-OMe phenylalkynyl modified compounds.
3.3. Effect of 2-bromo 13-epiestrone on OATP2B1-mediated estrone-3-
sulfate uptake
Inhibition of hormone uptake by OATP2B1 in tumor cells could be
the major goal of the newly identified inhibitors. Therefore, in order to
Fig. 2. A) Western blot detection of OATP2B1
expressed in A431 cells. OATP2B1 was de-
tected by an anti-OATP2B1 antibody [27], and
β-actin was used as a loading control. Control
(ctr.) stands for mock transfected A431 cells.
Multiple migratory bands may represent dif-
ferentially glycosylated forms of OATP2B1. B)
Zombie Violet uptake in A431-OATP2B1 and
control cells. Histograms show the uptake of
ZV (250x dilution) in the cells incubated with
the fluorescent dye for 15min at 37 °C in up-
take buffer (pH 5.5). Living (propidium-iodide
negative) cells are shown. Mock transfected
cells are indicated with a red line and
OATP2B1 transfected are with blue.
Fig. 3. Inhibition of dye uptake in A431-
OATP2B1 cells by halogenated 13-epiestrones.
A431-OATP2B1 cells and their mock trans-
fected counterparts were incubated in the pre-
sence or absence of increasing amounts of the
13-epiestrones (1-100 μM, as indicated on the x
axis) with the Zombie Violet dye for 30min at
37 °C. Fluorescence was measured in an Enspire
plate reader. Fluorescence obtained in mock
transfected A431 cells was subtracted from that
measured in A431-OATP2B1 cells. Transport
was calculated based on the fluorescence
measured in the absence of 13-epiestrones (100
%). Data points show the average +/- SD va-
lues obtained in at least three independent
biological replicates.
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determine whether the best performing newly identified inhibitor, 2-
bromo-13-epiestrone (compound 1b_2) can be applied to inhibit hor-
mone uptake, we determined its effect on 3H-E1S uptake in A431
control and A431-OATP2B1 cells. Fig. 6 shows that compound 1b_2 can
attenuate E1S uptake mediated by OATP2B1, therefore it is a good
candidate to block hormone uptake in OATP2B1 expressing cells.
3.4. SAR analysis
Since the compounds under study do all possess a common core
structure (scaffold) with largest variance in terms of different sub-
stituents in positions C-2 and C-4, it appears interesting to perform
Structure-Activity Relationship (SAR) analysis for positions C-2 and C-4
separately. The rationale behind is that the increase or decrease of
bioactivities within a congeneric SAR series of compounds can possibly
be explained by the variations in physicochemical properties at a spe-
cific substitution site (R or X-group site). However, since the initial
(parent) compounds 3-OH and 3-OMe are possessing very different
inhibitory potential (EC50 value of compound 1 (3-OH) is 50 μM while
for compound 2 (3-OMe) is 2.98 μM), we have performed the SAR
analysis for 3-OH and 3-OMe derivatives separately.
In the case of the 3-OH derivatives, the SAR analysis (Table 3) for
substituents at position C-2 shows that the number of atoms and heavy
atoms in the substituent is negatively correlated with activity (R =
-0.89 and -0.84). Of equal effect is the number of aromatic carbocycles
in that side chain: possessing no rings is more favorable (R = -0.90).
Further, molar refractivity (‘SMR’) which reflects the charge distribu-
tion and hence corresponds to the polarizability of a given functional
group is inversely correlated to bioactivity: less polarizable is more
favourable (R = -0.88). Also Labute’s Approximative Surface Area
(‘LabuteASA’) (R = -0.82) [29] - a measure of the size of a molecules’
surface area - as well as the partition coefficient (‘SlogP’) are negatively
correlated (R = -0.73) to activity, corresponding to a favorable lower
size and lipophilicity of substituents at position C-2. Concrete values of
Pearson correlation coefficients for given descriptors are listed in
Table 3 (a heat map representation of correlation values is given in
Supplementary Figure S1).
The only significant positive correlation at position C-2 was iden-
tified for the HallKier Alpha index (‘HallKier α’, R=0.88), as in-
troduced by Hall and Kier (equation nr. 58 in provided reference) [30].
HallKier α belongs to the class of topological descriptors which can
quantify molecular shape similarity within a set of molecules. HallKier
α relates to the size contribution of a query fragment to C(sp3)-hy-
bridized atoms, which are taken as a reference (HallKier α for sp3
carbon equals to 0). HallKier α thus encodes the effect of both covalent
radius and hybridization state of a given group of atoms. From Sup-
plementary Table 1 it becomes clear that the halogenated derivatives
are generally having positive HallKier α values and the phenylalkynyl
compounds are showing negative values. Interestingly, in the case of 3-
OMe derivatives none of the investigated physicochemical properties of
the C-2 substituents showed a meaningful correlation with the bioac-
tivity values of these compounds.
In contrast to substituents at position C-2, the SAR analysis for
substituents at position C-4 did not allow to prioritize physicochemical
features influencing the overall bioactivity on OATP2B1 (Table 3 and
Supplementary Figure S1). In general, correlations of physicochemical
features and bioactivity for substituents in position C-4 are comparable
for both 3-OH and 3-OMe derivatives. Most strikingly, the number of
heteroatoms of substituents at position C-4 is slightly negatively cor-
related with bioactivity for both 3-OH and 3-OMe derivatives (R =
-0.47 and -0.45). Due to the chemical composition of our compounds,
this effect points to an unfavorable effect of electronegative atoms at
this position (Cl, I, Br, F) which is inverse to the trends observed for
position C-2 (where halogens seem to be favorable).
Table 1
Inhibition of OATP2B1 activity by C-2 or C-4 halogenated 13-epiestrones.
compound "name" EC50± SD (μM) compound "name" EC50± SD (μM) compound "name" EC50± SD (μM) compound "name" EC50± SD (μM)
1 5̴0 2 2.98
± 0.05
1a_2 1.52 1a_4 6.63 2a_2 6.34 2a_4 8.14
± 0.01 ± 0.01 ± 0.02 ±0.02
1b_2 0.54 1b_4 10.8 2b_2 22.88 2b_4 18.6
± 0.02 ± 0.02 ± 0.02 ±0.02
1c_2 2.11 1c_4 >50 2c_2 10.89 2c_4 >50
±0.02 ± 0.03
The inhibitory effect of 13-epiestrones was measured using Zombie Violet as a test substrate [26]. The kinetic parameters of inhibition shown on Fig. 3 were determined by the
Graphpad Prism software.
Fig. 4. Structure of the phenylalkynyl modified 13-epiestrones investigated in the current study.
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4. Discussion
Recognizing numerous clinically applied drugs and promoting their
intestinal, hepatic and central nervous system (through the blood-brain-
barrier) uptake, OATP2B1 is a key determinant of drug pharmacoki-
netics [31]. Hence understanding the mechanism of its substrate/in-
hibitor recognition can promote drug development and may also help in
predicting/avoiding adverse effects caused by OATP2B1 mediated
drug-drug interactions. In addition, OATP2B1 is a dedicated conjugated
steroid hormone transporter. Its steroid hormone substrates are E1S,
pregnenolone-sulfate and DHEAS [32,33]. OATP2B1 has been identi-
fied as a key uptake transporter of DHEAS and E1S in the placenta and
mammary gland that are largely dependent on these hormone pre-
cursors [15,34]. In addition, OATP2B1 expressed in endothelial cells of
the blood-brain barrier is considered as an important mediator of the
uptake of the neuroactive steroids DHEAS and pregnenolone-sulfate
into the brain [35]. On the other hand, increased steroid hormone
uptake by OATP2B1 may also be favorable for tumor progression, as
was demonstrated in breast and prostate cancer [36,37]. Therefore,
inhibition of OATP2B1 function may be an alternative/successful
strategy to inhibit the growth of various tumors.
During the last two decades, since OATP2B1 was cloned [27], nu-
merous inhibitors of OATP2B1 have been described. Most of these are
clinically applied drugs, like cyclosporin A, rifampicin and statins
[38,39]. However these compounds are also inhibiting other drug
transporters, like P-glycoprotein [40] and additional OATPs or even
CYP enzymes [6,41], therefore they are lacking OATP2B1 specificity. In
addition, various steroids, e.g. estrone or testosterone that are them-
selves not transported by OATP2B1 have been documented as
OATP2B1 inhibitors [32]. However, besides again the lack of specifi-
city, these steroids are not effective inhibitors, since only low levels of
inhibition could be observed even at concentrations well above their
physiological occurrence. Grube et al. documented only 20–30 % de-
crease in OATP2B1-mediated E1S uptake by the application of 10 or
100 μM testosterone or estrone, respectively [32].
13-epiestrones represent a new class of OATP2B1 inhibitors. They
have no steroidogenic effect, hence their application may be void of
side effects. In our preliminary work we found that phosphonated 13-
epiestrones are potent inhibitors of OATP2B1 function, with EC50 va-
lues in the micromolar range [24]. In order to map the molecular de-
terminants of this inhibition, here we analyzed the inhibitory effect of a
series of 3-hydroxy or 3-methylether 13-epiestrones containing a
second, C-2 or C-4 halogen or phenylalkynyl modification. Compound
1, (3-OH 13-epiestrone) showed no interaction with OATP2B1 (EC50
around 50 μM), but the 3-methoxy counterpart compound 2 (3-OMe
13-epiestrone) performed a strong interaction (EC50 2.98 μM). In-
troduction of a second modification on C-2 or C-4 resulted in various
effects. In the case of 3-OMe 13-epiestrones, the second modification
issued in a decrease or loss of inhibitory activity with the exception of
2-iodo or 4-iodo (2a_2 and 2a_4), (4-fluorophenyl)ethynyl (2fS_4), (2-
methoxyphenyl)ethynyl (2gS_2) and (4-methoxyphenyl)ethynyl
(2gS_4) derivatives having similar EC50 values as the initial compound
3-OMe 13-epiestrone. In contrast, in the case of 13-epiestrone, the
second modification had various effects depending on the site (C-2 or C-
4) or nature (halogen or phenylalkynyl) of the substitution. In general,
introduction of a phenylalkynyl substituent did not result in potent
inhibitors. The only exception was the C-4 modified compound 1gS_4
having an EC50 value well below 10 μM. However, the most striking
change in the inhibitory effect was observed in the case of the 2-halo-
genated 13-epiestrones (1a_2, 1b_2 and 1c_2). These compounds po-
tently inhibited OATP2B1 function with EC50 values between 0.5 and
2.1 μM. In addition, halogenated 13-epiestrones revealed a strong re-
gioselectivity, 4-halogenated compounds showing no or very weak in-
hibition of OATP2B1 activity. This C-2 halogen preference has already
been observed in the case of 2-iodo-estrone-3-sulfate [42]. Banerjee and
colleagues have demonstrated that 2-[125I]-estrone-3-sulfate is trans-
ported by OATP2B1 while transport in the case of its 4-iodo counterpart
could not be observed.
SAR analysis by R-group decomposition was performed in order to
elucidate molecular determinants potentially being responsible for
bioactivity of 13-epiestrones. Different potency of respective com-
pounds was correlated to the subtle changes in physico-chemical
properties at a specific R or X -group position. It has to be emphasized
that the observed trends are showing correlations of side chain features
and bioactivity, but these correlations are not necessarily pointing to a
causal relationship of activity and chemical descriptor value. In other
words, some of the correlations we see might be artefacts caused by
high intercorrelation of related features (e.g. molecular weight and li-
pophilicity are often intercorrelated). The presence of halogens in po-
sition C-2 was identified to drive the activity against OATP2B1. The
importance of fluor and 4-fluorophenyl functional groups for OATP2B1
substrate activity was already demonstrated by the substructural frag-
ment analysis performed by Shaikh et al. [43]. Our findings are sug-
gesting the likelihood of halogen bond formation in OATP2B1-ligand
binding complexes. As an outlook, we suggest to prove such a hy-
pothesis by e.g. molecular docking combined with quantum mechanics
techniques. SAR analysis of functional groups at position C-4 delivered
negative correlation with the number of heteroatoms. These trends,
however, appear to be less pronounced for position C-4 substituents and
therefore it is required to repeat the analyses with a bigger data set
showing a larger range of structural variations in this position for fur-
ther investigations. SAR analysis revealed that 3-OH derivatives are
showing more pronounced positive and negative correlation with dif-
ferent physicochemical properties at position C-2. In general, 3-OH
derivatives are more sensitive to the substitutions at position C-2 when
compared to 3-OMe derivatives.
In our previous study we investigated 3-hydroxy, 3-methylether and
3-benzylether (3-OBn) 13-epiestrones with a C-2 or C-4 diethyl phos-
phono or diphenylphosphine oxide substitution [24]. In that study, in
accordance with our current findings, we found that the second (C-2 or
C-4) modification results in dramatic increase in the inhibitory poten-
tial of 13-epiestrone (3-OH). Also in harmony with our current results,
Table 2
Inhibition of OATP2B1 activity by C-2 or C-4 phenylalkynylated 13-epiestrones.
compound "name" EC50± SD (μM) compound "name" EC50± SD (μM) compound "name" EC50± SD (μM) compound "name" EC50± SD (μM)
1dS_2 15.53 1dS_4 11.55 2dS_2 >50 2dS_4 12.83
± 0.03 ± 0.02 ±0.04
1eS_2 >50 1eS_4 11.36 2eS_2 20.77 2eS_4 11.86
± 0.02 ± 0.03 ±0.02
1fS_2 12.95 1fS_4 >50 2fS_2 >50 2fS_4 8.73
± 0.01 ±0.02
1gS_2 11.08 1gS_4 4.57 2gS_2 3.79 2gS_4 3.4
± 0.04 ± 0.01 ± 0.05 ±0.02
1hS_2 9.27 1hS_4 >50 2hS_2 10.5 2hS_4 46.09
± 0.04 ± 0.03 ±0.04
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Fig. 5. Inhibition of dye uptake in A431-OATP2B1 cells by phenylalkynylated 13-epiestrones. Inhibition of Zombie Violet uptake in A431-OATP2B1 and mock
transfected cells was measured as described at Fig. 3. Average +/- SD values obtained in at least three independent biological replicates are shown.
R. Laczkó-Rigó, et al. Journal of Steroid Biochemistry and Molecular Biology 200 (2020) 105652
7
the second modification could not further improve the potent inhibition
by 3-OMe 13-epiestrone. However, in the case of phosphonated 13-
epiestrones, the OATP2B1 inhibitory action did not substantially de-
pend on the regioisomerism (C-2 vs. C-4).
HSD17β1 and STS are key enzymes in local estrogen production.
Inhibition of their activity by specific or more desirably by dual in-
hibitors could be a good strategy to prevent tumor progression [44].
The most promising STS inhibitor STX-64, Irosustat performed well in
phase I trial, however the phase II trial was not that satisfactory [44],
suggesting the need for combined treatment with HSD17β1 inhibitors
[45]. Moreover, it has been demonstrated that blocking the aromatase
pathway resulted in the upregulation of the STS enzyme and OATPs
[46]. Therefore, simultaneous blockage of the different estrogen me-
tabolic pathways and the function of the steroid uptake transporter
OATPs could be the only successful strategy to inhibit hormone de-
pendent cancers. Our experiments show that the newly identified best
performing inhibitor, 2-bromo-13-epiestrone (compound 1b_2) can be
used to inhibit OATP2B1-mediated E1S uptake (Fig. 6). Some of the
inhibitors identified in our current study, including compound 1b_2,
are also potent inhibitors of the HSD17β1 enzyme (see Table 4),
therefore they can be good candidate dual inhibitors to be tested in
hormone dependent cell lines.
Although OATP2B1 is not related evolutionally to the STS and
HSD17β enzyme families, considering their overlapping inhibitor spe-
cificities, one may speculate that knowledge gathered from the in-
hibitor recognition profile of these enzymes can be used to design ef-
fective inhibitors of OATP2B1. This is especially important since a
protein structure of OATPs is not yet available. Therefore, we have
compared the inhibition data obtained in the current study for
OATP2B1 with that previously measured for HSD17β1 and STS en-
zymes [21,25]. Table 4 shows, that inhibition of HSD17β1 reveals few
similar features to that of the inhibition of OATP2B1.
Namely, HSD17β1 also has a C-2 preference and both 2-halogenated
and phenylalkynyl conjugates potently inhibit HSD17β1 function. Also,
similarly to OATP2B1, 3-OMe 13-epiestrones are less effective in-
hibitors of HSD17β1. However, C-4 halogenation of 3-OMe 13-epies-
trones also results in effective inhibitors that is in contrast to that ob-
served for OATP2B1. Unfortunately, data about the effect of the 13-
epiestrones investigated in the current study on STS activity are in-
complete. Nevertheless, although estrone-3-sulfate is a common sub-
strate of OATP2B1 and STS, based on the interaction with halogenated
13-epiestrones, opposite inhibitor preference could be observed for
OATP2B1 and STS. STS was only inhibited by some of the C-4 halo-
genated compounds that were not the most effective inhibitors of
OATP2B1. We suggest that a larger data set of HSD17β1, STS, OATP
and 13-epiestrone interactions should be generated in order to de-
termine whether common trends in structural elements important for
their inhibition can be observed. Also it would be interesting to in-
vestigate the inhibitory effect of 13-epiestrones on the function of other
OATPs up-regulated in hormone dependent cancers, OATP1A2,
OATP1B3, OATP3A1 and OATP4A1 [47]. On the other hand, hepatic
OATPs, 1B1, 1B3 and 2B1 have overlapping substrate specificities,
hence, although desirable, specific inhibitors amenable to distinguish
between their function are scarce. The OATP2B1 inhibitor 13-epies-
trones (1a_2, 1b_2 and 1c_2) identified in the current study can be good
candidates to be tested for OATP1B interaction.
In summary, we identify potent inhibitors of OATP2B1. The EC50 of
the most potent inhibitor 2-bromo-13-epiestrone falls within the range
Fig. 6. Inhibition of 3H-E1S uptake in A431-OATP2B1 cells by 2-bromo-13-
epiestrone (1b_2). A431-OATP2B1 cells and their mock transfected counter-
parts were incubated in the presence or absence of 50 μM 1b_2 with 9.65 nM
3H-E1S for 10min at 37 °C. The radioactivity was measured by Wallac Liquid
Scintillator Counter. Radioactivity obtained in mock transfected A431 cells was
subtracted from that measured in A431-OATP2B1 cells. Transport was calcu-
lated based on the measured radioactivity of 3H-E1S in the absence of 2-bromo-
13-epiestrone (100 %). Data points show the average +/- SD values obtained in
three independent biological replicates. Significance was calculated with
GraphPad Prism, using unpaired t-test, ****P < 0.0001.
Table 3
Pearson correlation coefficients for physico-chemical descriptors at position C-2
and C-4.
A) 3-OH derivatives
Descriptor name Pearson correlation coefficient
Position C-2 Position C-4
NumAtoms −0.89 0.01
NumHeavyAtoms −0.84 −0.13
NumHeteroAtoms 0.23 −0.47
NumAromaticCarbocycles −0.90 −0.06
SMR −0.88 0.08
LabuteASA −0.82 −0.03
SlogP −0.73 −0.26
HallKierAlpha 0.88 0.13
B) 3-OMe derivatives
Descriptor name Pearson correlation coefficient
Position C-2 Position C-4
NumAtoms −0.05 0.31
NumHeavyAtoms −0.06 0.20
NumHeteroAtoms 0.39 −0.45
NumAromaticCarbocycles −0.21 0.30
SMR −0.05 0.39
LabuteASA −0.01 0.28
SlogP −0.08 −0.04
HallKierAlpha 0.16 −0.23
Table 4
Comparison of the inhibitory effect of 13-epiestrones on OATP2B1, HSD17β1
and STS activity.
C-3 C-2 C-4 Inhibition of
OATP2B1
(determined in
the current
study)
Inhibition of
HSD17β1
(as described
earlier in
[21,25])
STS (as
described
earlier in
[21])
OH H H non + non
halogen H +/++ ++ non
phenylalkynyl H non ++ +/non
H halogen +/non + +/non
H phenylalkynyl +/non non non
OMe H H + + n.d.
halogen H +/non non n.d.
phenylalkynyl H non non n.d.
H halogen +/non ++ n.d.
H phenylalkynyl +/non non n.d.
Columns labeled with C-2, C-3 or C-4 indicate modifications on the 2nd, 3rd or
4th carbon of 13-epiestrone. n.d.: no data available.
+: EC50 below 10 μM.
++: EC50 below 1 μM.
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of previously documented OATP2B1 inhibitors (BSP 1.26 μM [26],
antivirals: 0.5–1 μM, erlotinib: 0.03 μM [48] and E1S: 0.56 μM [26].
However, although potent inhibitors were identified, our assay cannot
distinguish between an inhibition caused by transported substrates or
non-competitive inhibitors. Further experiments, e.g. measurement of
direct uptake of the best performing 13-epiestrones (showing the
highest inhibition) are needed to clarify this issue. Still, one may
speculate that if OATP2B1 can mediate the uptake of these HSD17β1
inhibitors, a more potent anti-tumor effect can be achieved in tumors
expressing both HSD17β1 and OATP2B1. Since certain 2-halogenated-
13-epiestrones, and the previously investigated phosphonated 13-
epiestrones [24] are dual inhibitors of HSD17β1 and OATP2B1, their
effect on the survival of hormone dependent cell lines with OATP2B1
overexpression, and/or HSD17β1 expression is reasonable to be in-
vestigated.
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